Evidence of intrapulmonary penetration of nacubactam, a novel β-lactamase inhibitor, following coadministration of nacubactam with meropenem in healthy adults
Antimicrobial Agents and Chemotherapy · 03.06.2026 · 70 (6)
DOI: 10.1128/aac.00026-26 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.06.2026. Verfasst von Jun Morita und 7 weiteren Autor:innen. Beteiligte Einrichtung: Meiji Seika Pharma Co., Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Lung, Meropenem, Azabicyclo Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biomedical Advanced Research and Development Authority.
Abstract (Originalsprache)
Nacubactam is a novel non-β-lactam β-lactamase inhibitor being developed in combination with β-lactam antibiotics to treat serious gram-negative bacterial infections including nosocomial pneumonia. This study evaluated the systemic and intrapulmonary pharmacokinetics and safety of nacubactam plus meropenem in healthy adult male and female volunteers. Post-treatment bronchoalveolar lavage (BAL) to collect lung epithelial lining fluid (ELF). A total of 21 healthy adult participants were enrolled to receive a single dose of nacubactam 2 g coadministered with meropenem 2 g, of whom 20 underwent BAL and collection of blood samples for plasma pharmacokinetic (PK) characterization. The ratios of ELF to plasma area under the concentration-time curve from 0 to 8 h were 0.271 for nacubactam and 0.183 for meropenem. The estimated nacubactam half-life in ELF was 1.82 h and that in plasma was 1.71 h. PK data for meropenem were aligned with previously published results, with lower concentrations in ELF compared with plasma. The intrapulmonary penetration of nacubactam was favorable, with an area under the curve ratio (epithelial lining fluid to plasma) of 0.271, which was comparable to or greater than that observed for other approved β-lactamase inhibitors. The treatment combination was well tolerated, and no significant safety signals were identified. These data support further consideration of nacubactam/β-lactam combinations for the treatment of serious nosocomial pneumonia. CLINICAL TRIALS This study was registered with ClinicalTrials.gov as NCT03182504 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Meiji Seika Pharma Co., Ltd., Tokyo, Japan.
- Roche Pharma Research and Early Development, Roche Innovation Centre New York, Little Falls, New York, USA.
- Global Product Development, Roche Products Limited, Welwyn Garden City, United Kingdom.
- Roche Pharma Research and Early Development, Roche Innovation Centre New York, New York, New York, USA.
ORCID-Profile: Jun Morita, Navita L Mallalieu
Förderung
- Biomedical Advanced Research and Development Authority
Zitieren
APA
Morita, J., Ishiwata, K., Matsumoto, S., Kato, S., Attley, G., Patel, K., Rodriguez, I., & Mallalieu, N. L. (2026). Evidence of intrapulmonary penetration of nacubactam, a novel β-lactamase inhibitor, following coadministration of nacubactam with meropenem in healthy adults. Antimicrobial Agents and Chemotherapy, 70(6). https://doi.org/10.1128/aac.00026-26
Vancouver
Morita J, Ishiwata K, Matsumoto S, Kato S, Attley G, Patel K, et al. Evidence of intrapulmonary penetration of nacubactam, a novel β-lactamase inhibitor, following coadministration of nacubactam with meropenem in healthy adults. Antimicrobial Agents and Chemotherapy. 2026;70(6). doi:10.1128/aac.00026-26
BibTeX
@article{Morita2026,
author = {Morita, Jun and Ishiwata, Kazuya and Matsumoto, Shogo and Kato, Seiji and Attley, Gemma and Patel, Katie and Rodriguez, Ignacio and Mallalieu, Navita L},
title = {Evidence of intrapulmonary penetration of nacubactam, a novel β-lactamase inhibitor, following coadministration of nacubactam with meropenem in healthy adults},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {6},
doi = {10.1128/aac.00026-26}
}
EUVIMED